A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

Trial Details

NCT ID
NCT05838521
Phase
PHASE2
Sponsor
Yale University
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Sacituzumab govitecan
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Patients must have radiologically confirmed (i.e., CAT scan and/or MRI) persistent or recurrent histologically confirmed cervical cancer of epithel…
  • Must have availability of archival tumor tissue FFPE block for TROP-2 testing
  • Chemotherapy administered concurrent with primary radiation (i.e., weekly cisplatin) is not counted as a systemic chemotherapeutic regimen for mana…
  • All patients must have measurable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →